Trials / Recruiting
RecruitingNCT05139238
Postpartum Hypertension Study
Oral Nifedipine Versus Intravenous Labetalol for Postpartum (PP) Hypertensive Emergency: A Randomized Clinical Trial (RCT)
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- Sponsor
- Columbia University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess which blood pressure medication (intravenous labetalol or oral nifedipine) works better in treating severely elevated blood pressure in women who have just delivered a baby.
Detailed description
Hypertensive emergencies cause significant maternal morbidity and mortality in the postpartum period. In order to reduced these risks, the recommendation is to treat women with severe range blood pressure with either intravenous labetalol or oral nifedipine; it is unclear which medication is superior. The objective of this study is to prospectively enroll women who have hypertensive emergencies in the postpartum period; women will be randomized in a 1:1 fashion and treated with one of the two antihypertensives to see which one works better.
Conditions
- Postpartum Pregnancy-Induced Hypertension
- Postpartum Preeclampsia
- Pregnancy-Induced Hypertension in Postpartum
- Hypertensive Emergency
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Labetalol | Intravenous labetalol, a short acting ant-hypertensive |
| DRUG | Nifedipine | Oral nifedipine, a short acting ant-hypertensive |
Timeline
- Start date
- 2022-07-04
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2021-12-01
- Last updated
- 2025-04-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05139238. Inclusion in this directory is not an endorsement.